NCT00274794View on ClinicalTrials.gov

VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL

NACompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

February 29, 2000

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
Lymphoma
Interventions
BIOLOGICAL

filgrastim

10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide

BIOLOGICAL

rituximab

375 mg/m2, IV, Once per week for 3 weeks.

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Institute, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

The Cleveland Clinic

OTHER

NCT00274794 - VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL | Biotech Hunter | Biotech Hunter